CHMJF - Chemistree Technology Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1376
+0.0037 (+2.74%)
At close: 2:03PM EDT
Stock chart is not supported by your current browser
Previous Close0.1339
Open0.1317
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1201 - 0.1409
52 Week Range0.0350 - 0.5790
Volume4,053
Avg. Volume23,184
Market Cap4.65M
Beta (3Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.0350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire

    Chemistree Cancels PCCBD Investment

    VANCOUVER, Oct. 7, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE:CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), announces that the proposed investment into The Physician's Choice CBD ("PCCBD") of Phoenix, Arizona, as previously announced in April 2019, has been terminated. Chemistree president Karl Kottmeier commented: "I am disappointed to report that after many months of meetings, discussions and attempts to manage an increasingly frustrating process, Chemistree has decided that the proposed $1 million investment into what we believed was a compelling and unique company, cannot be made. Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry.

  • PR Newswire

    Chemistree Applauds Initial Success for Safe Banking Act in U.S.

    VANCOUVER, Sept. 26, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE:CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to provide shareholders with comments on the passage yesterday of the Secure and Fair Enforcement Banking Act of 2019 (SAFE Banking Act) by the United States House of Representatives. "Chemistree decided early in its history to focus on developing its business in the legal cannabis industry in certain states in the US. Members of our management team, our Board of Directors and major shareholders have long been significant influencers in the legal cannabis industry in the United States." commented president Karl Kottmeier.

  • PR Newswire

    Chemistree Provides Washington State Update from Sugarleaf

    VANCOUVER, Sept. 24, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE:CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to provide shareholders with an update on the Company's Washington State assets. Chemistree has received a strongly positive report from the general manager of its Washington state licensee partner detailing the successes as previously reported in April have in fact been exceeded. Chemistree is also pleased to announce that Sugarleaf has requested that additional cultivation facilities be made available at the Sedro Wooley location, on the same turn-key basis as currently in place, so Sugarleaf can expand its capacity to double its current level and meet the rapidly growing demand for Sugarleaf branded products.

  • PR Newswire

    Chemistree Completes Investment in New Jersey Cannabis Applicant - ACS

    VANCOUVER, July 22, 2019 /PRNewswire/ - Chemistree Technology Inc. (CHM.CN) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that through a wholly owned U.S. subsidiary, the Company has finalized its investment into Applied Cannabis Sciences of New Jersey ("ACS"), a New Jersey-based medical vertically integrated applicant, previously announced as a letter of intent (press release dated April 15, 2019). ACS will be submitting its application in the upcoming New Jersey round of Request for Applications (RFA), which was released Monday, July15, 2019 by the New Jersey Department of Health. The State will issue 24 new permits, comprising of 15 dispensary permits, 5 cultivation permits, and 4 vertically integrated permits.

  • CNW Group

    Chemistree Announces Resignation of Non-Executive Chairman

    VANCOUVER , June 14, 2019 /CNW/ - Chemistree Technology Inc. (CHM.CN) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), announces that Non-executive Chairman of the board, Justin Chorbajian has tendered his resignation. Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry.  The Company's corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management's decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities.

  • CNW Group

    Chemistree Comments on Recent Promotional Activity at Request of OTC Markets

    VANCOUVER , June 13, 2019 /CNW/ - Chemistree Technology Inc. (CHM.CN) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), has been requested by OTC Markets Group to comment on recent promotional activity. The Company first became aware of certain promotional third-party newsletter activities through a notification by OTC Markets on June 11, 2019 . The Company takes its investor relations practices seriously, including its obligations to release material information which might reasonably be expected to have significant effect on the market price or value of its securities.

  • CNW Group

    Chemistree Partner, ACS, to File New Jersey Application Under New DOH Mandate

    VANCOUVER , June 10, 2019 /CNW/ - Chemistree Technology Inc. (CHM.CN) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that its partner Applied Cannabis Sciences of New Jersey ("ACS"), is readying an Application under the new Request for Applications (RFA) program announced by the Department of Health on June 3, 2019 . New Jersey's State Legislature also passed a medical marijuana program expansion bill (Senate Nos. It is anticipated that New Jersey Governor Phil Murphy will sign the bill into law once the aforementioned RFA is underway.

  • CNW Group

    Chemistree Acquires Ownership Stake in The Physician's Choice CBD LLC

    VANCOUVER , April 29, 2019 /CNW/ - Chemistree Technology Inc. (CSE:CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the Company has entered into a funding agreement with The Physician's Choice CBD LLC of Phoenix, Arizona . The Physician's Choice CBD ("PCCBD") is dedicated to research, development, and utilization of the highest quality of hemp-derived cannabidiol (CBD) combined with well-studied and effective supplements specific to help regulate and support various symptoms. In it's first quarter of sales ended January 2019 , the company booked approximately $150,000 in sales.

  • PR Newswire

    Chemistree Provides California and Washington Operations Update

    VANCOUVER, April 18, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE:CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to provide shareholders with an update on the Company's Washington State assets and its Desert Hot Springs, California cultivation facility development. With the full support of Chemistree as landlord and turnkey  equipment provider, this group of people continue to do a tremendous job in restoring Sugarleaf to its previous place in the Washington market for flower and pre-rolled products as well as introducing new exciting products to the market.

  • CNW Group

    Chemistree Announces Partnership with New Jersey Medical Retail Cannabis License Applicant

    VANCOUVER , April 15, 2019 /CNW/ - Chemistree Technology Inc. (CHM.CN) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that its wholly owned U.S. subsidiary, American CHM Investments Inc., has signed a letter of intent (LOI) to partner with Applied Cannabis Sciences of New Jersey ("ACS"), a New Jersey -based medical retail dispensary applicant in the upcoming New Jersey round of Request for Applications (RFA), which is anticipated in 2020. Applied Cannabis Sciences has been established by a team of seasoned professionals from the legal medicinal and adult use marijuana industry whose collective experience exceeds 50 years and includes over 20 cultivation, processing, and manufacturing licenses across four states ( Washington , Oregon , California , and Colorado ) within the U.S. The ACS team is predominantly made up of professionals that reside and currently operate from New Jersey and maintain multiple strategic relationships.

  • PR Newswire

    Chemistree Appoints Industry Leading Cultivation Expert and Cannabis Grow Consultant, Sheldon Aberman as its Chief Cannabis Officer

    VANCOUVER, April 11, 2019 /PRNewswire/ - Chemistree Technology Inc. (CSE:CHM and CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree"), is pleased to announce the appointment of Mr. Sheldon Aberman to the newly-created position of Chief Cannabis Officer.  This addition will further strengthen its team and advance the Company's international expansion strategy, cultivation practices and results in terms of yield, quality, consistency and cost-effectiveness as it continues to execute across these areas and solidify its position as a world leader within the industry. Mr. Aberman has a well-earned reputation as one of the world's foremost experts on commercial cannabis cultivation with decades of experience managing and designing thousands of grows worldwide.  His expertise, hands on approach and product development background has led to top quality grow room design and construction.  Additionally, he has created several multi-million-dollar industry partnerships and other ventures, such as Quantum Horticulture, Pure Essentials Black Label and Cannabis Consulting Co. whose various products and services have been implemented, utilized and run in thousands of grows globally.

  • GlobeNewswire

    Cannabis Sticks to its Roots: Cannabis Companies Continue to Prioritize the Importance of “People”

    Chemistree Technology Inc. (CSE:CHM) (OTCQB: CHMJF), an investment company dedicated to the US cannabis sector endeavoring to provide turn-key solutions for the regulated cannabis industry, recently announced the addition of Nicholas J. Zitelli, a.k.a. Mr. Zitelli is a well-known cannabis industry leader.

  • CNW Group

    Chemistree appoints Nico Escondido to Board of Directors

    Mr. Zitelli is currently part-owner, Director, and Chief Cannabis Officer of Trans High Corporation (THC), the parent company for all HIGH TIMES brands, including its 45-year old flagship magazine, as well as all related media and event platforms, including the iconic Cannabis Cup. Since 2007, Mr. Zitelli has authored hundreds of articles covering all aspects of cannabis science and technology under the penname of "Nico Escondido". In this capacity, Mr. Zitelli has garnered a reputation as an industry expert in the areas of cultivation, genetics, garden technologies, lab testing, and regulatory and compliance measures.